Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial

[Figure: see text] OBJECTIVES: Patients with Kawasaki disease can develop life-altering coronary arterial abnormalities, particularly in those resistant to intravenous immunoglobulin (IVIg) therapy. We tested the tumor necrosis factor α receptor antagonist etanercept for reducing both IVIg resistanc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatrics
Autors principals: Portman, Michael A., Dahdah, Nagib S., Slee, April, Olson, Aaron K., Choueiter, Nadine F., Soriano, Brian D., Buddhe, Sujatha, Altman, Carolyn A.
Format: Artigo
Idioma:Inglês
Publicat: American Academy of Pediatrics 2019
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6564061/
https://ncbi.nlm.nih.gov/pubmed/31048415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1542/peds.2018-3675
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars